AskBio Secures US FDA IND Clearance for AB-1009 Gene Therapy in Late-Onset Pompe Disease

AskBio Secures US FDA IND Clearance for AB-1009 Gene Therapy in Late-Onset Pompe Disease

By, Admin 15 January 2026

AskBio Inc., a gene therapy company wholly owned by Bayer AG, has received US FDA acceptance for its Investigational New Drug application for AB-1009.

This milestone allows the AB-1009 program to advance into Phase 1/2 clinical development in the United States.

What the FDA IND Acceptance Means?

The FDA clearance enables AskBio to begin a first-in-human clinical trial evaluating the safety of AB-1009 in patients with late-onset Pompe disease.

Key highlights include:

  • AB-1009 is an investigational AAV-based gene therapy
  • The Phase 1/2 trial will be conducted in the US
  • First patient enrollment is expected in early 2026

This marks a critical transition from preclinical research to clinical evaluation.

Strategic Collaboration with Belief BioMed

The AB-1009 program is supported by a strategic collaboration between AskBio and Belief BioMed (BBM), announced in September 2024.

Under this collaboration:

  • BBM sublicensed its proprietary AAV capsid to AskBio
  • BBM provided AAV vector production services
  • Both teams worked closely during IND-enabling activities

BBM’s technical and manufacturing contributions played a key role in achieving IND acceptance.

Leadership Perspective on the Milestone

Dr. Xiao Xiao, Co-founder and Chief Science Officer of Belief BioMed, highlighted the significance of the achievement.

He emphasized the strength of the partnership, AskBio’s R&D execution, and the value of global collaboration in advancing gene therapies.

Understanding Late-Onset Pompe Disease

Pompe disease is a rare, inherited lysosomal storage disorder caused by deficiency of acid alpha-glucosidase (GAA).

This deficiency leads to glycogen accumulation in cells, resulting in progressive muscle damage.

Key disease characteristics include:

  • Severe skeletal muscle weakness
  • Diaphragmatic involvement and respiratory insufficiency
  • A wide clinical spectrum from infantile to late-onset forms

Late-onset Pompe disease primarily affects skeletal muscles and progresses more slowly than the infantile form.

Globally, Pompe disease is estimated to affect between 5,000 and 10,000 people.

About AB-1009

AB-1009 is designed as a one-time AAV gene therapy intended to address the underlying genetic cause of Pompe disease.

By enabling sustained GAA expression, the therapy aims to reduce glycogen accumulation and slow disease progression.

About Belief BioMed

Belief BioMed is a global biotech company focused on gene therapy research, manufacturing, and clinical development.

The company has built:

  • Proprietary AAV capsid and vector platforms
  • Commercial-scale viral vector manufacturing capabilities
  • A broad pipeline across rare and chronic genetic diseases

Several BBM programs are already in clinical development, with regulatory approvals achieved in China.

Why This Development Matters?

The IND acceptance for AB-1009 reflects continued momentum in gene therapy innovation for rare neuromuscular diseases.

It also highlights the growing role of strategic partnerships in accelerating clinical translation for complex genetic disorders.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!